MA71659A - Compositions pour l'administration de molécules de charge utile à l'épithélium des voies respiratoires - Google Patents
Compositions pour l'administration de molécules de charge utile à l'épithélium des voies respiratoiresInfo
- Publication number
- MA71659A MA71659A MA71659A MA71659A MA71659A MA 71659 A MA71659 A MA 71659A MA 71659 A MA71659 A MA 71659A MA 71659 A MA71659 A MA 71659A MA 71659 A MA71659 A MA 71659A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- respiratory tract
- payload molecules
- tract epithelium
- delivering payload
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062367P | 2020-08-06 | 2020-08-06 | |
| EP21762908.8A EP4192433A2 (fr) | 2020-08-06 | 2021-08-06 | Compositions pour l'administration de molécules de charge utile à l'épithélium des voies respiratoires |
| PCT/US2021/045038 WO2022032154A2 (fr) | 2020-08-06 | 2021-08-06 | Compositions pour l'administration de molécules de charge utile à l'épithélium des voies respiratoires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71659A true MA71659A (fr) | 2025-05-30 |
Family
ID=77543659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71659A MA71659A (fr) | 2020-08-06 | 2021-08-06 | Compositions pour l'administration de molécules de charge utile à l'épithélium des voies respiratoires |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230285310A1 (fr) |
| EP (1) | EP4192433A2 (fr) |
| JP (1) | JP2023538260A (fr) |
| KR (1) | KR20230087443A (fr) |
| CN (1) | CN116348147A (fr) |
| AU (1) | AU2021320426A1 (fr) |
| BR (1) | BR112023001955A2 (fr) |
| CA (1) | CA3189854A1 (fr) |
| IL (1) | IL300111A (fr) |
| MA (1) | MA71659A (fr) |
| MX (1) | MX2023001461A (fr) |
| TW (1) | TW202214215A (fr) |
| WO (1) | WO2022032154A2 (fr) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4023249T3 (da) | 2014-04-23 | 2025-01-13 | Modernatx Inc | Nukleinsyrevacciner |
| MA42543A (fr) | 2015-07-30 | 2018-06-06 | Modernatx Inc | Arn épitope peptidiques concatémériques |
| CA3003090A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins anticancereux |
| HRP20220872T1 (hr) | 2015-10-22 | 2022-12-23 | Modernatx, Inc. | Cjepiva protiv respiratornih virusa |
| ES2928475T3 (es) | 2016-09-14 | 2022-11-18 | Modernatx Inc | Composiciones de ARN de alta pureza y métodos para su preparación |
| CN110167587A (zh) | 2016-11-11 | 2019-08-23 | 摩登纳特斯有限公司 | 流感疫苗 |
| WO2018187590A1 (fr) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
| WO2019036685A1 (fr) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | Procédés pour analyse par clhp |
| MA49913A (fr) | 2017-08-18 | 2021-05-05 | Modernatx Inc | Variants d'arn polymérase |
| EP3746090A4 (fr) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | Vaccins à base d'arn contre le vrs |
| EP3853305B1 (fr) | 2018-09-19 | 2024-10-02 | ModernaTX, Inc. | Lipides peg de haute pureté et leurs utilisations |
| WO2020061284A1 (fr) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Lipides peg et leurs utilisations |
| US11980673B2 (en) | 2018-10-09 | 2024-05-14 | The University Of British Columbia | Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto |
| CA3132975A1 (fr) | 2019-03-11 | 2020-09-17 | Modernatx, Inc. | Procede de transcription in vitro a alimentation semi-discontinue |
| EP3938379A4 (fr) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | Vaccins à base d'arn contre le vih |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| EP4274607A1 (fr) | 2021-01-11 | 2023-11-15 | ModernaTX, Inc. | Vaccins contre le virus de la grippe à arn saisonnière |
| EP4312987A4 (fr) | 2021-03-22 | 2025-02-26 | Recode Therapeutics, Inc. | Compositions et procédés pour un apport ciblé à des cellules |
| US20250019409A1 (en) | 2021-03-23 | 2025-01-16 | Recode Therapeutics, Inc. | Polynucleotide compositions, related formulations, and methods of use thereof |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| EP4423108A1 (fr) * | 2021-10-29 | 2024-09-04 | ModernaTX, Inc. | Amines lipidiques |
| JP2024542001A (ja) * | 2021-10-29 | 2024-11-13 | モデルナティエックス インコーポレイテッド | 脂質アミン |
| CN118829423A (zh) * | 2021-11-12 | 2024-10-22 | 摩登纳特斯有限公司 | 用于将有效载荷分子递送至气道上皮的组合物 |
| WO2023154818A1 (fr) | 2022-02-09 | 2023-08-17 | Modernatx, Inc. | Méthodes et formulations d'administration par voie muqueuse |
| EP4479082A2 (fr) * | 2022-02-15 | 2024-12-25 | The Broad Institute, Inc. | Système d'injection contractile de ciblage spécifique de type cellule |
| US20250188028A1 (en) * | 2022-03-14 | 2025-06-12 | Nanovation Therapeutics Inc. | Synthetic Method for Producing Ionizable Amino Lipids |
| CN117355558A (zh) * | 2022-04-12 | 2024-01-05 | 厦门赛诺邦格生物科技股份有限公司 | 一种氮支化非线性聚乙二醇化脂质及其应用 |
| CN117003808A (zh) * | 2022-04-28 | 2023-11-07 | 北京科兴中维生物技术有限公司 | 一种阳离子脂质化合物及其制备方法和用途 |
| KR20250061730A (ko) * | 2022-08-08 | 2025-05-08 | 어드밴스드 알엔에이 백신 (에이알브이) 테크놀로지스, 아이엔씨. | 스테롤 기반 이온화 가능한 지질 및 이를 포함하는 지질 나노입자 |
| WO2024089633A1 (fr) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Molécules d'arn codant pour le vrs-f et vaccins les contenant |
| WO2024095179A1 (fr) | 2022-11-04 | 2024-05-10 | Pfizer Inc. | Composés lipidiques et leurs utilisations |
| EP4630057A1 (fr) | 2022-12-08 | 2025-10-15 | Recode Therapeutics, Inc. | Compositions de nanoparticules lipidiques et leurs utilisations |
| KR20250106303A (ko) * | 2022-12-19 | 2025-07-09 | 후지필름 가부시키가이샤 | 치료제를 전달하는 방법, 및 지질 조성물 |
| EP4658636A1 (fr) | 2023-01-31 | 2025-12-10 | Pfizer Inc. | Composés lipidiques et leurs utilisations |
| KR20250151427A (ko) * | 2023-02-13 | 2025-10-21 | 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 | 치료적 조성물을 위한 절단성 링커 함유 이온화 가능한 지질 및 지질 담체 |
| AU2024250062A1 (en) * | 2023-04-14 | 2025-10-23 | Beijing Jitai Life Sciences Ltd | Lipid nanoparticle compositions and uses thereof |
| WO2024229297A1 (fr) * | 2023-05-02 | 2024-11-07 | Sage Therapeutics, Inc. | Composés de ciblage de système lymphatique |
| AU2024265267A1 (en) * | 2023-05-03 | 2025-11-20 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| WO2025027492A1 (fr) | 2023-07-31 | 2025-02-06 | Pfizer Inc. | Variants d'antigène de coronavirus |
| WO2025034764A1 (fr) * | 2023-08-07 | 2025-02-13 | Life Technologies Corporation | Lipides pour l'administration d'acides nucléiques à des cellules eucaryotes |
| US12364773B2 (en) | 2023-12-01 | 2025-07-22 | Recode Therapeutics, Inc. | Lipid nanoparticle compositions and uses thereof |
| WO2025126019A1 (fr) | 2023-12-13 | 2025-06-19 | Pfizer Inc. | Molécules d'arn |
| WO2025126071A1 (fr) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Molécules d'arn |
| WO2025126113A1 (fr) | 2023-12-15 | 2025-06-19 | Pfizer Inc. | Composés lipidiques et leurs utilisations |
| WO2025126118A1 (fr) | 2023-12-15 | 2025-06-19 | Pfizer Inc. | Composés lipidiques et leurs utilisations |
| CN121015606A (zh) * | 2024-01-19 | 2025-11-28 | 晟迪生物医药(苏州)有限公司 | 含有可电离脂质的肺部递送系统、其制备方法和应用 |
| WO2025180481A1 (fr) * | 2024-03-01 | 2025-09-04 | 北京剂泰医药科技有限公司 | Composé lipidique pegylé, nanoparticules lipidiques associées, composition associée et utilisation associée |
| WO2025186725A2 (fr) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Formulations de npl améliorées et leurs utilisations |
| WO2025207803A1 (fr) * | 2024-03-26 | 2025-10-02 | General Therapeutics, Inc. | Composés lipidiques, compositions et méthodes d'utilisation associées |
| CN120718086A (zh) * | 2024-06-13 | 2025-09-30 | 仁景(苏州)生物科技有限公司 | 用于递送的脂质化合物和脂质纳米颗粒 |
| WO2026018181A1 (fr) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Compositions immunogènes et leurs utilisations |
| WO2026030275A1 (fr) | 2024-08-01 | 2026-02-05 | Pfizer Inc. | Molécules d'arn |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
| US6071890A (en) * | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5840710A (en) * | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US5925628A (en) * | 1997-03-31 | 1999-07-20 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
| US5942634A (en) * | 1997-05-09 | 1999-08-24 | Genzyme Corporation | Cationic amphiphiles for cell transfections |
| US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| CA2597724A1 (fr) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Compositions a base de nanoparticules lipidiques et methodes pour l'administration de molecules biologiquement actives |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| AU2008219165A1 (en) | 2007-02-16 | 2008-08-28 | Merck Sharp & Dohme Corp. | Compositions and methods for potentiated activity of biologicaly active molecules |
| WO2009051451A2 (fr) * | 2007-10-17 | 2009-04-23 | Korea Advanced Institute Of Science And Technology | Nanoparticules cationiques du type ldl destinées à délivrer un gène d'acide nucléique, procédé de préparation de celles-ci et procédé destiné à délivrer ce gène d'acide nucléique au moyen de ces nanoparticules |
| US20110224447A1 (en) | 2008-08-18 | 2011-09-15 | Bowman Keith A | Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids |
| WO2010080724A1 (fr) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Nanoparticules lipidiques inédites et composants inédits utilisables pour l'administration d'acides nucléiques |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| WO2011000107A1 (fr) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Formulations lipidiques inédites permettant l'administration d'agents thérapeutiques en direction de tumeurs solides |
| ES2579936T3 (es) | 2009-08-20 | 2016-08-17 | Sirna Therapeutics, Inc. | Nuevos lípidos catiónicos con diversos grupos de cabeza para el suministro oligonucleotídico |
| WO2011043913A2 (fr) | 2009-10-08 | 2011-04-14 | Merck Sharp & Dohme Corp. | Nouveaux lipides cationiques à chaînes lipidiques courtes pour une administration d'oligonucléotides |
| RS58405B1 (sr) | 2009-12-01 | 2019-04-30 | Translate Bio Inc | Stereoidni derivati za isporuku irnk u humanim genetskim oboljenjima |
| US9670487B2 (en) | 2010-01-22 | 2017-06-06 | Sirna Therapeutics, Inc. | Cationic lipids for oligonucleotide delivery |
| US9254327B2 (en) | 2010-05-10 | 2016-02-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| JP2013527856A (ja) | 2010-05-12 | 2013-07-04 | プロチバ バイオセラピューティクス インコーポレイティッド | 陽イオン性脂質およびその使用方法 |
| WO2011149733A2 (fr) | 2010-05-24 | 2011-12-01 | Merck Sharp & Dohme Corp. | Nouveaux lipides cationiques alcools aminés pour l'administration d'oligonucléotides |
| DK2575767T3 (en) | 2010-06-04 | 2017-03-13 | Sirna Therapeutics Inc | HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES |
| US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| US9669097B2 (en) | 2010-09-20 | 2017-06-06 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
| EP2621480B1 (fr) | 2010-09-30 | 2018-08-15 | Sirna Therapeutics, Inc. | Lipides cationiques de faible masse moléculaire utilisables en vue de l'administration d'oligonucléotides |
| LT4108671T (lt) | 2010-10-01 | 2025-01-10 | Modernatx, Inc. | Modifikuoti nukleozidai, nukleotidai, nukleorūgštys bei jų panaudojimas |
| CN103153347A (zh) | 2010-10-21 | 2013-06-12 | 默沙东公司 | 用于寡核苷酸递送的新型低分子量阳离子脂质 |
| EP2635265B1 (fr) | 2010-11-05 | 2018-04-04 | Sirna Therapeutics, Inc. | Amine cyclique inédite de faible masse moléculaire contenant des lipides cationiques en vue de l'administration d'oligonucléotides |
| JP5902197B2 (ja) | 2011-01-11 | 2016-04-13 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | Ｐｅｇ化脂質および薬剤送達のためのそれらの使用 |
| CA3198966A1 (fr) | 2011-06-08 | 2012-12-13 | Translate Bio, Inc. | Lipides clivables |
| US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
| WO2013086373A1 (fr) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipides pour l'administration d'agents actifs |
| CA3165769A1 (fr) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipides biodegradables pour l'administration d'agents actifs |
| WO2013103659A1 (fr) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilisation d'arn par incorporation de nucléosides de terminaison à l'extrémité 3' |
| WO2013116126A1 (fr) | 2012-02-01 | 2013-08-08 | Merck Sharp & Dohme Corp. | Nouveaux lipides cationiques biodégradables de faible masse moléculaire pour la délivrance d'oligonucléotides |
| PT2817287T (pt) | 2012-02-24 | 2018-12-28 | Arbutus Biopharma Corp | Lípidos catiónicos trialquílicos e seus métodos de utilização |
| WO2014093924A1 (fr) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Molécules d'acide nucléique modifiées et leurs utilisations |
| KR20140048404A (ko) * | 2012-10-11 | 2014-04-24 | 포항공과대학교 산학협력단 | 저밀도 지단백질 유사 나노입자 및 이를 포함하는 간 표적 진단 및 치료용 조성물 |
| HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
| EP2964234A4 (fr) | 2013-03-09 | 2016-12-07 | Moderna Therapeutics Inc | Régions non traduites hétérologues pour arnm |
| EP2968391A1 (fr) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Molécules polynucléotidiques à longue durée de vie |
| US10342760B2 (en) | 2013-03-15 | 2019-07-09 | The University Of British Columbia | Lipid nanoparticles for transfection and related methods |
| PT3766916T (pt) | 2014-06-25 | 2022-11-28 | Acuitas Therapeutics Inc | Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos |
| WO2017075531A1 (fr) | 2015-10-28 | 2017-05-04 | Acuitas Therapeutics, Inc. | Nouveaux lipides et nouvelles formulations de nanoparticules de lipides pour l'administration d'acides nucléiques |
| JP7332478B2 (ja) * | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
| RS63953B1 (sr) * | 2017-03-15 | 2023-02-28 | Modernatx Inc | Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava |
| US11529314B2 (en) * | 2017-11-10 | 2022-12-20 | Board Of Regents, The University Of Texas System | Lipid-based nanoparticles for encapsulation and sustained release of therapeutic agents |
| BR112021014845A2 (pt) | 2019-01-31 | 2021-11-03 | Modernatx Inc | Métodos de preparação de nanopartículas lipídicas |
-
2021
- 2021-08-06 US US18/040,485 patent/US20230285310A1/en active Pending
- 2021-08-06 EP EP21762908.8A patent/EP4192433A2/fr active Pending
- 2021-08-06 MX MX2023001461A patent/MX2023001461A/es unknown
- 2021-08-06 BR BR112023001955A patent/BR112023001955A2/pt not_active Application Discontinuation
- 2021-08-06 CN CN202180068470.XA patent/CN116348147A/zh active Pending
- 2021-08-06 AU AU2021320426A patent/AU2021320426A1/en not_active Abandoned
- 2021-08-06 TW TW110129202A patent/TW202214215A/zh unknown
- 2021-08-06 MA MA71659A patent/MA71659A/fr unknown
- 2021-08-06 IL IL300111A patent/IL300111A/en unknown
- 2021-08-06 WO PCT/US2021/045038 patent/WO2022032154A2/fr not_active Ceased
- 2021-08-06 KR KR1020237007762A patent/KR20230087443A/ko not_active Withdrawn
- 2021-08-06 JP JP2023507600A patent/JP2023538260A/ja active Pending
- 2021-08-06 CA CA3189854A patent/CA3189854A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3189854A1 (fr) | 2022-02-10 |
| MX2023001461A (es) | 2023-04-26 |
| CN116348147A (zh) | 2023-06-27 |
| US20230285310A1 (en) | 2023-09-14 |
| AU2021320426A1 (en) | 2023-03-23 |
| JP2023538260A (ja) | 2023-09-07 |
| EP4192433A2 (fr) | 2023-06-14 |
| TW202214215A (zh) | 2022-04-16 |
| WO2022032154A3 (fr) | 2022-04-21 |
| IL300111A (en) | 2023-03-01 |
| BR112023001955A2 (pt) | 2023-04-11 |
| WO2022032154A2 (fr) | 2022-02-10 |
| KR20230087443A (ko) | 2023-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA71659A (fr) | Compositions pour l'administration de molécules de charge utile à l'épithélium des voies respiratoires | |
| NZ777871A (en) | Small molecule modulators of il-17 | |
| EP2605816A4 (fr) | Pulvérisateur circonférentiel pour administration de médicaments à l'épithélium olfactif et au cerveau | |
| MA51796A (fr) | Procédés et compositions pour l'administration de protéines thérapeutiques | |
| EP3813853A4 (fr) | Compositions pour l'administration de médicaments et leurs méthodes d'utilisation | |
| HRP20090077A2 (hr) | Modulatori farmakokinetičkih svojstava terapeutika | |
| MA51617A (fr) | Mécanisme d'administration de médicament | |
| MX2010001236A (es) | Derivados de 5-fenil-isoxazol-3-carboxamida como moduladores del receptor de potencial transitorio v1 (trpv1). | |
| RU2018133298A (ru) | Способы применения агонистов fxr | |
| JP2009532360A5 (fr) | ||
| MA34517B1 (fr) | Promédicaments comprenant un conjugué exendine-lieur | |
| WO2018042362A9 (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
| EA201992116A1 (ru) | Фармацевтические составы флороглюцинола и триметилфлороглюцинола | |
| EP3806939A4 (fr) | Appareil pour utilisation dans l'administration de médicaments pour les voies respiratoires | |
| EP3836866A4 (fr) | Systèmes d'administration entérique d'agents thérapeutiques | |
| EP3762036A4 (fr) | Conjugués peptidiques multivalents pour le traitement intra-articulaire prolongé d'une inflammation articulaire | |
| CY1120530T1 (el) | Απο του στοματος χορηγησιμη φαρμακευτικη συνθεση | |
| MX2023013683A (es) | Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). | |
| PH12022550937A1 (en) | Pharmaceutical composition comprising selexipag | |
| EP3886911A4 (fr) | Nanoparticules recouvertes de biomembrane (bionp) pour l'administration de principes actifs à des cellules souches | |
| FR2940116B1 (fr) | Formulation pour l'administration d'hypolipemiant par voie trans-muqueuse buccale | |
| BRPI0721255B8 (pt) | composições de olopatadina para administração nasal tópica | |
| HRP20190211T1 (hr) | Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti | |
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| IL320753A (en) | Pharmaceutical preparations for ocular administration |